Effect of astaxanthin intake in patients affected by type 2 diabetes mellitus

Effect of Astaxanthin intake on expression of miR-146a and miR-126 in plasma, oxidative stress and inflammation markers and glycemic profile, compared with placebo in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015081623645N1

Enrollment

Registered

2015-12-13

Start date

2015-10-07

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Non-insulin-dependent diabetes mellitus, Malnutrition-related diabetes mellitus

Interventions

Intervention 1: Using of food supplement contain 8 mg of Astaxanthin daily orally for 8-weeks Made in USA. Intervention 2: Use of a placebo pill containing starch and manufacture by Faculty of Pharma

Treatment - Drugs

Placebo

Using of food supplement contain 8 mg of Astaxanthin daily orally for 8-weeks Made in USA

Use of a placebo pill containing starch and manufacture by Faculty of Pharmacy of Ahvaz Jundishapur University of Medical Sciences for 8-weeks

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Willingness to participate in the study, age range between 30-60 years old, Body Mass Index range between 19 and 35 kg per m2, HbA1C more than seven, not to be affected by renal, liver, lung and autoimmune disease, normal thyroid status, patients who have received standard oral treatments for at least six months. Exclusion criteria:Failure to follow the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FBS. Timepoint: at first and two months after intervention. Method of measurement: glucose enzymatic kit.;Fructosamine. Timepoint: at first and two months after intervention. Method of measurement: ELISA.;HDL. Timepoint: at first and two months after intervention. Method of measurement: spectrophotometer.;LDL. Timepoint: at first and two months after intervention. Method of measurement: spectrophotometer.;TG. Timepoint: at first and two months after intervention. Method of measurement: spectrophotometer.;IL6. Timepoint: at first and two months after intervention. Method of measurement: Elisa kit.;Adiponectin. Timepoint: at first and 2 months after intervention. Method of measurement: ELISA.;MDA. Timepoint: at first and two months after intervention. Method of measurement: TBARS.	—

Measure

Time frame

FBS. Timepoint: at first and two months after intervention. Method of measurement: glucose enzymatic kit.;Fructosamine. Timepoint: at first and two months after intervention. Method of measurement: ELISA.;HDL. Timepoint: at first and two months after intervention. Method of measurement: spectrophotometer.;LDL. Timepoint: at first and two months after intervention. Method of measurement: spectrophotometer.;TG. Timepoint: at first and two months after intervention. Method of measurement: spectrophotometer.;IL6. Timepoint: at first and two months after intervention. Method of measurement: Elisa kit.;Adiponectin. Timepoint: at first and 2 months after intervention. Method of measurement: ELISA.;MDA. Timepoint: at first and two months after intervention. Method of measurement: TBARS.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNafiseh Shokri

Ahvaz Jundishapour University of Medical Sciences

nafiseh.shokri@yahoo.com , shokri.n@ajums.ac.ir+98 61 3373 8330

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026